The website of the Clinical Services Journal

Research on blood pressure allays COVID fears

Fears that people with high blood pressure are more at risk from severe COVID-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research involving UCLH.

 

The team including UCLH Director of Research Professor Bryan Williams led by the University of Manchester also showed that speculation that some blood pressure lowering medications may increase the risk of COVID-19 infection is likely to be wrong.

The study conducted on human kidneys, published in the European Heart Journal, will reassure doctors and their patients that it is safe to take their blood pressure medication during the pandemic.

Scientists already know that SARS-CoV-2 virus – which causes COVID-19 disease – uses a protein called ACE2 found on the surface of kidney and to a lesser extent lung and heart cells, as a way to infect the body.

Kidneys are the primary site for blood pressure regulation in the body. They naturally produce ACE2 at a higher level than many other tissues and are affected by the virus.

But the suggestion that ACE2 is modified by antihypertensive medicines, especially ACE inhibitors to make it easier for SARS-Cov-2 to break into cells, has been disproved by the team.

“There has been widely reported speculation that having high blood pressure and taking certain medications used to treat hypertension - especially ACE Inhibitors - may increase expression of the blood pressure regulating protein ACE2,” said Dr. James Eales, from The University of Manchester.

“Many felt that increased expression of ACE2 may also increase the risk of infection - or a severe outcome from SARS-CoV-2” added Dr. Xiao Jiang, from the University of Manchester.

Professor Fadi J Charchar from Federation University in Australia added: “We checked a range of antihypertensive medicines including, beta blockers, ACE inhibitors, Calcium Channel antagonists, Angiotensin II receptor blockers, and others; none are linked to changes in ACE2.”

Professor Bryan Williams added: “The speculation about whether high blood pressure and the drugs we commonly use to treat it, increased the risks associated with COVID-19 infection caused a lot of anxiety for many millions of people treated for high blood pressure. This new research refutes the prior speculation that the drugs we commonly use to treat high blood pressure leads to an increase in the receptors for COVID-19 on the surface of the lungs. It is a really important finding.”

Upcoming Events

Central Sterilising Club Annual Scientific Meeting

Crowne Plaza, Newcastle Upon Tyne
3rd - 4th April 2023

DECON UK 2023

Hilton Birmingham Metropole
18th April 2023

Infection Prevention and Control 2023

National Conference Centre, Birmingham
25th - 26th April 2023

Oncology Professional Care

ExCeL London E16 1XL
23-24 May 2023

EBME Expo 2023

Judds Lane, Coventry, England, GB, CV6 6
28th - 29th June 2023

AfPP Annual Conference 2023

University of York
10- 13 August 2023

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Upcoming Events

Central Sterilising Club Annual Scientific Meeting

Crowne Plaza, Newcastle Upon Tyne
3rd - 4th April 2023

DECON UK 2023

Hilton Birmingham Metropole
18th April 2023

Infection Prevention and Control 2023

National Conference Centre, Birmingham
25th - 26th April 2023

Oncology Professional Care

ExCeL London E16 1XL
23-24 May 2023

EBME Expo 2023

Judds Lane, Coventry, England, GB, CV6 6
28th - 29th June 2023

AfPP Annual Conference 2023

University of York
10- 13 August 2023

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2023 Step Communications Ltd. Registered in England. Registration Number 3893025